Takeda Pharmaceutical Company Limited TAK
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.26% | -0.54% | -1.29% | -2.14% | 1.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.26% | -0.54% | -1.29% | -2.14% | 1.39% |
| Cost of Revenue | 1.17% | 4.01% | -1.77% | 1.04% | 4.56% |
| Gross Profit | -1.03% | -2.91% | -1.04% | -3.78% | -0.24% |
| SG&A Expenses | -1.08% | -0.92% | 0.47% | -0.89% | 1.04% |
| Depreciation & Amortization | -14.03% | -7.40% | -1.08% | 79.11% | -0.89% |
| Other Operating Expenses | 106.01% | -25.58% | -38.95% | 462.04% | -35.42% |
| Total Operating Expenses | -1.71% | -1.49% | -1.26% | 9.11% | 0.58% |
| Operating Income | 10.20% | 6.22% | -1.52% | -47.40% | 7.62% |
| Income Before Tax | -162.25% | -169.40% | -8.75% | -60.38% | 328.54% |
| Income Tax Expenses | -36.77% | -77.94% | 275.59% | 389.12% | 153.11% |
| Earnings from Continuing Operations | -208.68% | -225.72% | -43.13% | -86.47% | -1.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -40.03% | -23.30% | -43.34% | -24.35% | -17.00% |
| Net Income | -209.03% | -226.21% | -43.21% | -86.54% | -1.63% |
| EBIT | 10.20% | 6.22% | -1.52% | -47.40% | 7.62% |
| EBITDA | -1.05% | 0.39% | -1.34% | -28.16% | 2.86% |
| EPS Basic | -208.13% | -224.36% | -42.60% | -86.16% | -1.48% |
| Normalized Basic EPS | 14.19% | 7.75% | 10.57% | -55.99% | 9.27% |
| EPS Diluted | -213.12% | -231.04% | -43.64% | -86.70% | -3.07% |
| Normalized Diluted EPS | 14.69% | 8.17% | 11.01% | -55.96% | 8.40% |
| Average Basic Shares Outstanding | 0.03% | -0.28% | -0.04% | 0.32% | 0.69% |
| Average Diluted Shares Outstanding | 0.05% | -0.22% | 0.01% | -0.06% | 1.17% |
| Dividend Per Share | 1.00% | 1.00% | 2.22% | 2.22% | 1.44% |
| Payout Ratio | -1.89% | -1.84% | 0.88% | 6.95% | 0.09% |